Dexcom (DXCM)
NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
$73.57+1.64%
Close 2026-07-07 · 1-day change
Reading DXCM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DXCM free→NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
Reading DXCM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DXCM free→Warn: Management is running behind on a stated commitment.
Dexcom grows sales about 10% a year through 2030. Profit margins improve to about 29-30%. The company keeps gross margins near 67-69%. It also buys back $1 billion of stock. These show strong growth and good cash use.
Growth could slow below 10% a year. Profit margins might stay near 22-23%, below targets. Competition or product issues could hurt sales and margins.
The price is about 15% below our fair value near $87. Analysts expect about 14% revenue growth. Our view aligns with this but sees margin improvement as key upside.
Breaks if: Gross margin falls below 63% beyond FY26
Dexcom aims to maintain a Non-GAAP Gross Profit Margin of 67-69% by 2030.
Stated in 3 of last 3 quarters. The Non-GAAP Gross Profit Margin guidance for 2026 is 63-64%, with a target of 67-69% by 2030. The trajectory shows a focus on maintaining margins, though current levels are below the long-term target.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Dexcom: '2030 Non-GAAP Gross Profit Margin of 67-69%.”
“Non-GAAP Gross Profit Margin of approximately 63-64%.”
“Non-GAAP Gross Profit Margin of approximately 61%.”
Breaks if: Operating margin remains below 22% beyond FY26
Dexcom is focused on improving its Non-GAAP Operating Margin to 29-30% by 2030.
Stated in 3 of last 3 quarters. The Non-GAAP Operating Margin guidance for 2026 is 22-23%, with a long-term target of 29-30% by 2030. The trajectory indicates a focus on margin improvement, though current margins are below the long-term target.
“Dexcom: '2030 Non-GAAP Operating Profit Margin of 29-30%.”
“Non-GAAP Operating Margin of approximately 22-23%.”
“Non-GAAP Operating Margin of approximately 20-21%.”
Breaks if: YoY revenue growth falls below 10% in any year through 2030
Dexcom aims to achieve organic revenue growth of 10%+ every year through 2030.
Stated in 3 of last 3 quarters. Revenue guidance for 2026 is set at $5.16 - $5.25 billion, indicating an 11-13% growth over 2025. The trajectory shows consistent focus on revenue growth, with guidance reflecting this priority.
“Dexcom: 'Organic Revenue growth of 10%+ every year through 2030.'”
“Dexcom currently anticipates total revenue of $5.16 - $5.25 billion, representing expected growth of approximately 11-13% over 2025.”
“Dexcom is raising fiscal year 2025 guidance for Revenue, and updating guidance for Non-GAAP Gross Profit Margin.”
Breaks if: Share repurchase program is canceled or materially delayed
Dexcom announced a new share repurchase program of up to $1.0 billion.